Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

160.41 +0.16 (+0.10%)
Streaming Delayed Price Updated: 3:47 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
News headline image
Is Big Pharma Coming For Your Cannabis Business? ↗
Cannabis stocks have struggled in the market in recent years as the industry push to gain ground on the regulatory front hasn't progressed as quickly as investors had hoped. Yet beverage companies... 
Via Benzinga
News headline image
My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years ↗
The cannabis sector has been disappointing in recent years, but this company stands out. 
Via The Motley Fool
News headline image
Medical Marijuana Milestone In The UK: Celadon Pharmaceuticals Becomes First Company With License To Sell In Britain ↗
Celadon Pharmaceuticals has become the first UK-based medical cannabis manufacturer to be granted a Home Office license to sell its products in the UK.  
Via Benzinga
News headline image
Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries ↗
Last week the US economy got clobbered by the biggest banking collapse since 2008 when the parent of Silicon Valley Bank, SVB Financial Group (NASDAQ: SIVB) failed to raise enough capital to continue. 
Via Benzinga
News headline image
Zymeworks Offers Hope for More than Just Long-Term Investors
Zymeworks stock is up nearly 5% since reporting earnings and a rally that has put ZYME stock over 25% in the last 12 months and could send the stock higher 
Via MarketBeat
News headline image
The Latest Analyst Ratings for Jazz Pharmaceuticals ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 1, 2023 ↗
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
News headline image
Earnings Preview For Jazz Pharmaceuticals ↗
 
Via Benzinga
News headline image
With Access To $20 Million In Financing, 1606 Corp Is Eyeing CBD Business Acquisitions As It Embarks On An Aggressive Growth Path ↗
The global CBD market is on an upward trajectory, and there are no indications that the growth could be slowing down anytime soon. The market was valued at $5.18 billion in 2021 and is expected to... 
Via Benzinga
News headline image
Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying ↗
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) recently published collected data on CBD safety, placing the information under its Yellow Card alert system, which lists various... 
Via Benzinga
News headline image
Why Cannabis Is Recession-Resistant & Turning Challenges Into Opportunities, Industry Expert Explains ↗
It is safe to say that the cannabis industry would not have progressed as much as it has if it were not for the people who believed in it. Cannabis advocates, lobbyists, growers, operators, consumers... 
Via Benzinga
News headline image
Jazz Q4 2022 Revenue Grows 8% To $972M, Provides Outlook ↗
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Q4 2022 revenue was $972.12 million an 8% increase compared to 896.73 million in Q4 2021. Financial Highlights 
Via Benzinga
Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart? ↗
 
Via Benzinga
News headline image
2 Cannabis Stocks to Buy for the Long Haul ↗
Don't give up on this sector too quickly. 
Via The Motley Fool
News headline image
Cannabis-Based Medicine As A Potential Treatment For Psychosis, An Oxford University Study Says ↗
The Department of Psychiatry at the University of Oxford will conduct an international study to investigate whether cannabis-based medicine can treat psychosis. 
Via Benzinga
News headline image
Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling ↗
The company only just gained approval for its depression drug in August. 
Via Investor's Business Daily
News headline image
GlycoMimetics Audio Discussion And Analysis With Dan Cohen And Scott Matusow ↗
Dan Cohen and Scott Matusow discuss In this 1:11 audio the upcoming data sets for Glycomimetics. We talk about The Company's platform chemistry in depth, and give our predictions for success/failure of... 
Via Talk Markets
News headline image
2 Cannabis Stocks That Could Make You Richer ↗
These two stocks could grow like weeds in the next five years and beyond. 
Via The Motley Fool
News headline image
CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHS ↗
The National Health Service England confirmed Tuesday that starting this week, doctors can prescribe Jazz Pharmaceuticals (NASDAQ: JAZZ) Epidiolex, a CBD-based medicine, to patients suffering from... 
Via Benzinga
News headline image
3 Cannabis Stocks With Double-Digit Percentage Revenue Growth ↗
Their shares may be down, but their sales are up. 
Via The Motley Fool
News headline image
The Ultimate Growth Stocks to Buy With $300 Right Now ↗
These three companies should deliver inflation-busting long-term growth. 
Via The Motley Fool
News headline image
2 Promising New Growth Stocks to Watch in 2023 ↗
These stocks have plenty of room to run. 
Via The Motley Fool
News headline image
Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer ↗
 
Via Benzinga
News headline image
2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher ↗
There are still plenty of growth opportunities left for these businesses. 
Via The Motley Fool
News headline image
These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy. ↗
These stocks look cheap if you take a long-term view. 
Via The Motley Fool
News headline image
Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court ↗
Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS 
Via Benzinga
News headline image
2 Growth Stocks to Buy Heading Into 2023 ↗
These biotechs are far from having achieved their full potential. 
Via The Motley Fool
News headline image
2 Top Biotech Stocks to Buy for the Long Haul ↗
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
News headline image
Better Buy: Moderna vs Axsome ↗
Revenue prospects look promising for both of these biotech companies. 
Via The Motley Fool
News headline image
Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today ↗
U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.